Efficacy of Fractional Carbon Dioxide Laser Combined With Platelet-rich Plasma

Efficacy of Ablative Fractional Carbon Dioxide Laser Combined With Autologous Platelet-rich Plasma Versus Ablative Fractional Carbon Dioxide Laser and Placebo in the Treatment of Striae Gravidarum: a Randomized Clinical Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04956367

Enrollment

Registered

2021-07-09

Start date

2019-07-01

Completion date

2019-11-30

Last updated

2021-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Striae Gravidarum

Keywords

Striae Gravidarum, carbon dioxide laser, platelet-rich plasma

Brief summary

This study determined the efficacy of ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma versus ablative fractional carbon dioxide laser with placebo in the treatment of striae gravidarum of postpartum Filipino women.

Interventions

PROCEDUREAblative fractional carbon dioxide laser combined with autologous platelet-rich plasma

Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.

DEVICECO2 laser with PRP

CO2 laser with PRP

DEVICECO2 laser with placebo

CO2 laser with placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Masking description

Used a computer-generated software to randomize the area to be treated.

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Postpartum patients with ages 18 to 45 years * Fitzpatrick skin type III-V * having bilateral symmetrical SG of red, white or a combination of both types.

Exclusion criteria

* pregnancy * breastfeeding * heavy consumption of alcoholic beverages * dermatological conditions such as psoriasis, systemic lupus erythematosus and atopic dermatitis * uncontrolled hypertension, diabetes mellitus, heart disease, acute and chronic liver/kidney impairment/disease; * elevated liver function tests (SGPT, SGOT), and serum creatinine; * intake of any medications that may influence the outcome of the study; * intake of any vitamins/minerals or any supplements in the past 6 months; and * application of any topical agents (e.g., whitening, anti-aging) in the past 6 months

Design outcomes

Primary

Measure	Time frame	Description
Clinical improvement	16 weeks	Change in appearance based from clinical photos done in baseline, week 6, week 10, week 14 and week 16 . This will be assessed by quartile grading scale (poor, \<25% improvement; fair, 25-50% improvement; good, 51-75% improvement; and excellent, \>75% improvement)

Secondary

Measure	Time frame	Description
Patient satisfaction rate	16 weeks	Self-reported by the patient using a quartile grading system with the following grades: 0 as poor; 1 as fair; 2 as satisfied; or 3 as very satisfied. The rating will be done at weeks 6, 10, 14 and 16.

Countries

Philippines

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026